Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells

Table 1 Pathologic features and inhibition of cell growth by 10058-F4 in primary culture cells of ovarian carcinoma

Patient ID	AGE	Diagnosis	Stage	Grade	IC50 (uM)	c-MYC
avb	65	Serous	IIIA	G1	27	Positive
OC2	72	Serous	IIIC	G3	84	Positive
OC3	48	Serous	IIA	G1	28	Positive
OC4	36	Serous	IC	G1	56	Positive
OC5	66	Serous	IIIA	G1	26	Positive
OC6	61	Mucous	IIIA	G2	>100	Positive
OC7	55	Serous	IIIC	G3	N	Positive
OC8	51	Serous	IIA	G3	62	Positive
OC9	69	Serous	IIIC	G3	>100	Positive
OC10	53	Serous	IIIA	G1	30	Positive
OC11	38	Mucous	IA	G1	>100	Positive
OC12	47	Serous	IIIC	G3	N	Positive
OC13	64	Mucous	IIIA	G1	18	Positive
OC14	66	Serous	IIIC	G3	N	Positive
OC15	62	Serous	IIIA	G2	>100	Positive
OC16	57	Serous	IIIA	G1	22	Positive
OC17	43	Serous	IIA	G3	33	Positive
OC18	51	Serous	IIIC	G3	16	Positive

18 primary culture cells of ovarian cancer were cultured in 96 well plates or 6 well plates and treated with 10058-F4 as indicated doses. Cell proliferation was assessed by MTT assay.

ISSN: 1479-5876